Evidence map›Paper›PMID 37895899›Full record

ReviewPharmaceuticals (Basel, Switzerland)2023

Functionalizing Dendrimers for Targeted Delivery of Bioactive Molecules to Macrophages: A Potential Treatment for

Claudia Sanhueza, Daniela Vergara, Catalina Chávez-Aravena, Felipe Gálvez-Jiron, Emigdio Chavez-Angel, Alejandro Castro-Alvarez

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Mannose Ligands for Mannose Receptor Targeting.International journal of molecular sciences · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Claudia SanhuezaCentro de Excelencia en Medicina Traslacional (CEMT), Facultad de Medicina, Universidad de La Frontera, Temuco 4811230, Chile.ORCID 0000-0001-5558-5032
Daniela VergaraCentro de Excelencia en Medicina Traslacional (CEMT), Facultad de Medicina, Universidad de La Frontera, Temuco 4811230, Chile.ORCID 0009-0009-0654-2322
Catalina Chávez-AravenaDepartamento de Ciencias Preclínicas, Facultad de Medicina, Universidad de La Frontera, Temuco 4811230, Chile.
Felipe Gálvez-JironDoctorado en Ciencias Mención Biología Celular y Molecular Aplicada, Facultad de Medicina, Universidad de La Frontera, Temuco 4811230, Chile.
Emigdio Chavez-AngelCatalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, Campus UAB, Bellaterra, 08193 Barcelona, Spain.ORCID 0000-0002-9783-0806
Alejandro Castro-AlvarezDepartamento de Ciencias Preclínicas, Facultad de Medicina, Universidad de La Frontera, Temuco 4811230, Chile.ORCID 0000-0001-8360-8027
Universidad de La Frontera · CLInstitut Català de Nanociència i Nanotecnologia · ES

Funding

FONDECYT 11200620Postdoctoral FONDECYT project 3210533Postdoctoral FONDECYT project 3220479
6 · The paper itself

Abstract

Tuberculosis (TB) is an infectious disease caused by

Indexed as

dendrimershost directed therapymiRNAMycobacterium tuberculosistuberculosis

Identifiers

PMID37895899
PMCPMC10609949
OpenAlexW4387435101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.